INMB - INmune Bio Inc

6.84
-0.460   -6.725%

Share volume: 216,146
Last Updated: 04-08-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.07%

PREVIOUS CLOSE
CHG
CHG%
$7.30
-0.46
-0.06%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
38%
Profitability 25%
Dept financing 8%
Liquidity 75%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-5.91%
1 Month
-13.96%
3 Months
24.59%
6 Months
33.07%
1 Year
-35.23%
2 Year
-8.80%
Key data
Stock price
$6.84
P/E Ratio 
0.00
DAY RANGE
$6.77 - $7.64
EPS 
-$2.11
52 WEEK RANGE
$4.32 - $12.72
52 WEEK CHANGE
-$36.90
MARKET CAP 
93.140 M
YIELD 
N/A
SHARES OUTSTANDING 
19.761 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
2.02
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$285,875
AVERAGE 30 VOLUME 
$274,046
Company detail
CEO: Raymond J. Tesi
Region: US
Website: inmunebio.com
Employees: 10
IPO year: 2019
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.

Recent news
loading